Tara Gregory

1.1k total citations
31 papers, 557 citations indexed

About

Tara Gregory is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Tara Gregory has authored 31 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Hematology and 12 papers in Molecular Biology. Recurrent topics in Tara Gregory's work include CAR-T cell therapy research (18 papers), Multiple Myeloma Research and Treatments (10 papers) and Protein Degradation and Inhibitors (7 papers). Tara Gregory is often cited by papers focused on CAR-T cell therapy research (18 papers), Multiple Myeloma Research and Treatments (10 papers) and Protein Degradation and Inhibitors (7 papers). Tara Gregory collaborates with scholars based in United States, Canada and Japan. Tara Gregory's co-authors include Jesús G. Berdeja, Steven Trifilio, Ali McBride, Scott C. Howard, Yin Xiong, William Tse, David N. Wald, Devon J. Shedlock, Krina K. Patel and Adam D. Cohen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Tara Gregory

28 papers receiving 550 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tara Gregory United States	11	335	289	268	78	71	31	557
Adam J. Lamble United States	12	282 0.8×	159 0.6×	256 1.0×	147 1.9×	37 0.5×	54	548
Shebli Atrash United States	13	454 1.4×	403 1.4×	521 1.9×	112 1.4×	30 0.4×	119	752
Cristina Bugarin Italy	13	142 0.4×	153 0.5×	273 1.0×	197 2.5×	16 0.2×	26	605
H. A. Fritsche United States	7	166 0.5×	95 0.3×	89 0.3×	61 0.8×	37 0.5×	12	384
Dorothea Wessiepe Germany	5	497 1.5×	79 0.3×	117 0.4×	198 2.5×	58 0.8×	5	669
Houston Holmes United States	12	319 1.0×	88 0.3×	202 0.8×	119 1.5×	45 0.6×	39	540
Heiko Trautmann Germany	6	244 0.7×	112 0.4×	400 1.5×	57 0.7×	11 0.2×	15	716
Tse Hui Lim Singapore	14	175 0.5×	150 0.5×	74 0.3×	27 0.3×	10 0.1×	30	427
Reingard Stuhlmann Germany	9	267 0.8×	166 0.6×	521 1.9×	56 0.7×	15 0.2×	13	811
Raya Mawad United States	13	214 0.6×	127 0.4×	264 1.0×	98 1.3×	8 0.1×	38	459

Countries citing papers authored by Tara Gregory

Since Specialization

Citations

This map shows the geographic impact of Tara Gregory's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tara Gregory with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tara Gregory more than expected).

Fields of papers citing papers by Tara Gregory

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tara Gregory. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tara Gregory. The network helps show where Tara Gregory may publish in the future.

Co-authorship network of co-authors of Tara Gregory

This figure shows the co-authorship network connecting the top 25 collaborators of Tara Gregory. A scholar is included among the top collaborators of Tara Gregory based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tara Gregory. Tara Gregory is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Richard, Shambavi, Mahmoud Gaballa, Tara Gregory, et al.. (2025). Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study. Blood. 146(Supplement 1). 269–269.

Turner, Jacqueline A., et al.. (2025). Prophylactic Dexamethasone Rescues Unrestrained Lymphocyte Expansion in Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. Transplantation and Cellular Therapy. 31(2). S215–S216. 2 indexed citations

Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2024). Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network. Blood Advances. 9(2). 429–435. 4 indexed citations

Bal, Susan, Myo Htut, Jesús G. Berdeja, et al.. (2024). BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results. Blood. 144(Supplement 1). 2069–2069. 2 indexed citations

Gregory, Tara, et al.. (2024). Outcomes of Outpatient Administration of Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 7591–7591. 1 indexed citations

Strati, Paolo, Tara Gregory, Navneet S. Majhail, & Nitin Jain. (2023). Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review. JCO Oncology Practice. 19(9). 706–713. 6 indexed citations

Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2023). Access Barriers for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non-Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network. Transplantation and Cellular Therapy. 29(2). S55–S55. 2 indexed citations

Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2023). Outcomes for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network. Transplantation and Cellular Therapy. 29(2). S211–S211.

Furqan, Fateeha, Kwang Woo Ahn, Yue Chen, et al.. (2022). Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. British Journal of Haematology. 200(1). 54–63. 1 indexed citations

10.

Matous, Jeffrey, et al.. (2022). Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient. 18(1). 59–59. 2 indexed citations

11.

Slade, Michael, Thomas G. Martin, Nitya Nathwani, et al.. (2022). Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia. 36(12). 2917–2921. 10 indexed citations

12.

Bal, Susan, Mehmet H. Kocoglu, Omar Nadeem, et al.. (2022). Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study. Blood. 140(Supplement 1). 883–885. 32 indexed citations

13.

Nash, Richard A., Ted Gooley, Tara Gregory, et al.. (2021). Non-Myeloablative Hematopoietic Stem Cell Transplantation (NMA HSCT) Utilizing Low-Dose Total Body Irradiation (TBI) Plus Fludarabine (Flu): A Comparison of Single-Center Based Flu 150 mg/m2 Plus 400 Cgy TBI Versus Flu 90 mg/m2 and 200 Cgy TBI Containing Regimens. Transplantation and Cellular Therapy. 27(3). S226–S227.

14.

Berdeja, Jesús G., Tara Gregory, Edward A. Faber, et al.. (2021). A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort. American Journal of Hematology. 96(4). 428–435. 13 indexed citations

15.

Gregory, Tara, et al.. (2021). Latest Developments in Cellular Therapy for Multiple Myeloma. 16(2). 111–111. 2 indexed citations

16.

Costello, Caitlin, Tara Gregory, Syed Abbas Ali, et al.. (2019). Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME). Blood. 134(Supplement_1). 3184–3184. 43 indexed citations

17.

Vij, Ravi, Nitya Nathwani, Thomas Martin, et al.. (2018). Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. Blood. 132(Supplement 1). 123–123. 3 indexed citations

18.

Chen, George L., Paul A. Carpenter, Raewyn Broady, et al.. (2017). Anti–Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation. 24(2). 373–380. 10 indexed citations

19.

Howard, Scott C., et al.. (2016). Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Annals of Hematology. 95(4). 563–573. 86 indexed citations

20.

Gregory, Tara, et al.. (2009). Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. Journal of Hematology & Oncology. 2(1). 23–23. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact